Evaluations of Unformulated and Formulated Dendrimer-Based Microbicide Candidates in Mouse and Guinea Pig Models of Genital Herpes

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 12, 2003, Pages 3784-3788

  Bernstein, D I ^a   Stanberry, L R ^a,e   Sacks, S ^b   Ayisi, N K ^b   Gong, Y H ^b   Ireland, J ^a   Mumper, R J ^c   Holan, G ^d   Matthews, B ^d   McCarthy, T ^d   Bourne, N ^a,e  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b Viridae Clinical Sciences Inc   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d Starpharma Holdings Limited   (Australia)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DENDRIMER; SPL 7015; SPL 7032; UNCLASSIFIED DRUG; VIVAGEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; DRUG STRUCTURE; FEMALE; GENITAL HERPES; GUINEA PIG; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTIVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; FEMALE; GELS; GUINEA PIGS; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; MICE; MICROBIAL SENSITIVITY TESTS; POLYLYSINE;

EID: 10744228936     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.12.3784-3788.2003     Document Type: Article

References (19)

1. Bourne, N., D. I. Bernstein, J. Ireland, A. J. Sonderfan, A. T. Profy, and L. R. Stanberry. 1999. The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J. Infect. Dis. 180:203-205.
2. Bourne, N., J. Ireland, L. R. Stanberry, and D. I. Bernstein. 1999. Effect of undecylenic acid as a topical microbicide against genital herpes infection in mice and guinea pigs. Antivir. Res. 40:139-144.
3. Bourne, N., L. R. Stanberry, E. R. Kern, G. Holan, B. Matthews, and D. I. Bernstein. 2000. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob. Agents Chemother. 44:2471-2474.
4. Ebrahim, S. H., T. A. Peterman, A. A. Zaidi, and M. L. Kamb. 1997. Mortality related to sexually transmitted diseases in US women, 1973 through 1992. Am. J. Public Health 87:938-944.
5. Fisman, D. N., M. Lipsitch, E. W. Hook III, and S. J. Goldie. 2002. Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States. Sex. Transm. Dis. 29:608-622.
6. Fleming, D. T., G. M. McQuillan, R. E. Johnson, A. J. Nahmias, S. O. Aral, F. K. Lee, and M. E. St. Louis. 1997. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337:1105-1111.
7. Gong, Y., B. Matthews, D. Cheung, T. Tam, I. Gadawski, D. Leung, G. Holan, J. Raff, and S. Sacks. 2002. Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication. Antivir. Res. 55:319-329.
8. Koutsky, L. A., K. A. Ault, C. M. Wheeler, D. R. Brown, E. Barr, F. G. Alvarez, L. M. Chiacchierini, and K. U. Jansen. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-1651.
9. Mayer, K. H., S. A. Karim, C. Kelly, L. Maslankowski, H. Rees, A. T. Profy, J. Day, J. Welch, and Z. Rosenberg. 2003. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 17:321-329.
10. McCormack, S., R. Hayes, C. J. Lacey, and A. M. Johnson. 2001. Microbicides in HIV prevention. BMJ 322:410-413.
11. Smith, J. S., and N. J. Robinson. 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and 1. J. Infect. Dis. 186(Suppl.):S3-S28.
12. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, P. Vandepapeliere, and G. Dubin. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
13. Stanberry, L. R. 1991. Evaluation of herpes simplex virus vaccines in animals: the guinea pig vaginal model. Rev. Infect. Dis. 11(Suppl.):S920-S923.
14. Stone, A. 2002. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat. Rev. Drug Discov. 1:977-985.
15. Turpin, J. A. 2002. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin. Investig. Drugs 11:1077-1097.
16. Van Damme, L., G. Ramjee, M. Alary, B. Vuylsteke, V. Chandeying, P. Rees, L. Sirivongrangson, V. Mukenge-Tshibaka, C. Ettiegne-Traore, C. Uaheowitchai, S. S. Karim, B. Masse, J. Perriens, M. Laga, and the COL-1492 Study Group. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial. Lancet 360:971-977.
17. Wald, A., and K. Link. 2002. Risk of human immunodeficiency virus in herpes simplex virus type 2-seropositive persons: a meta analysis. J. Infect. Dis. 185:45-52.
18. Wilkinson, D., M. Tholandi, G. Ramjee, and G. W. Rutherford. 2002. Non-oxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomized controlled trials including more than 5000 women. Lancet Infect. Dis. 2:613-617.
19. Witvrouw, M., V. Fikkert, W. Pluymers, B. Matthews, K. Mardel, D. Schols, J. Raff, Z. Debyser, E. De Clercq, G. Holan, and C. Pannecouque. 2000. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol. Pharmacol. 58:1100-1108.